Literature DB >> 33457369

Skeletal Myopathy as the Initial Manifestation of Light Chain Multiple Myeloma.

Mohamed Reda Belkhribchia1, Sara Moukhlis2, Tarik Bentaoune3, Najat Chourkani4, Mohamed Zaidani5, Mehdi Karkouri2.   

Abstract

Monoclonal gammopathies due to plasma cell dyscrasias can cause various rare neuromuscular disorders. The peripheral nervous system is most commonly affected, while muscle diseases associated with monoclonal gammopathies are rare. Skeletal myopathy, as a manifestation in the context of multiple myeloma, is extremely uncommon and is usually the result of immunoglobulin light chain (AL) amyloidosis deposits in the muscles. Here we present an atypical case of a patient with generalized myopathy as the presenting manifestation of light chain multiple myeloma. Interestingly, muscle involvement in our case was not the consequence of AL amyloidosis deposits but rather due to non-amyloid light chain deposition disease associated with light chain multiple myeloma. LEARNING POINTS: Light chain multiple myeloma can present as myopathy.Creatine kinase and muscle biopsy specimens only examined using routine stains can be normal in this condition. © EFIM 2020.

Entities:  

Keywords:  Light chain deposition disease; chemotherapy; light chain multiple myeloma; monoclonal immunoglobulin deposition disease; skeletal myopathy

Year:  2020        PMID: 33457369      PMCID: PMC7806311          DOI: 10.12890/2020_002095

Source DB:  PubMed          Journal:  Eur J Case Rep Intern Med        ISSN: 2284-2594


  8 in total

1.  [A case of systemic AL amyloidosis diagnosed on muscle biopsy].

Authors:  Tomohiro Yata; Takashi Miwa; Katsuya Araki; Toru Kida; Keiko Toyooka; Ichizo Nishino; Chikao Tatsumi
Journal:  Rinsho Shinkeigaku       Date:  2019-12-17

Review 2.  Light chain deposition disease: novel biological insights and treatment advances.

Authors:  V H Jimenez-Zepeda
Journal:  Int J Lab Hematol       Date:  2012-04-04       Impact factor: 2.877

Review 3.  Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain, heavy-chain, and light- and heavy-chain deposition diseases.

Authors:  J Buxbaum; G Gallo
Journal:  Hematol Oncol Clin North Am       Date:  1999-12       Impact factor: 3.722

4.  An autopsy case of light chain deposition disease.

Authors:  N Kasahara; H Tamura; O Matsumura; R Nagasawa; Y Suzuki; T Ohgida; S Itoyama; T Mitarai; K Isoda
Journal:  Intern Med       Date:  1994-04       Impact factor: 1.271

5.  Expanding the spectrum of monoclonal light chain deposition disease in muscle.

Authors:  Lyle W Ostrow; Andrea M Corse; Brett M Morrison; Carol A Huff; John A Carrino; Ahmet Hoke; Andrew L Mammen
Journal:  Muscle Nerve       Date:  2012-05       Impact factor: 3.217

6.  Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival.

Authors:  Christopher P Venner; Thirusha Lane; Darren Foard; Lisa Rannigan; Simon D J Gibbs; Jennifer H Pinney; Carol J Whelan; Helen J Lachmann; Julian D Gillmore; Philip N Hawkins; Ashutosh D Wechalekar
Journal:  Blood       Date:  2012-02-13       Impact factor: 22.113

7.  AL amyloidosis presenting with limb girdle myopathy.

Authors:  Naveed Malek; Dominic G O'Donovan; Hadi Manji
Journal:  Pract Neurol       Date:  2018-07-24

Review 8.  An Overview of Light Chain Multiple Myeloma: Clinical Characteristics and Rarities, Management Strategies, and Disease Monitoring.

Authors:  Abdul Rafae; Mustafa N Malik; Muhammad Abu Zar; Seren Durer; Ceren Durer
Journal:  Cureus       Date:  2018-08-15
  8 in total
  1 in total

1.  Case Report: Monoclonal Gammopathies of Clinical Significance-Associated Myopathy: A Case-Based Review.

Authors:  Hongbin Yu; Du He; Qing Zhang; Bei Cao; Weiping Liu; Yu Wu
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.